Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Prospective study of patient-reported depression, and cognitive and functional impairment, and impact on survival and induction mortality in fit adults age ≥60 years receiving intensive chemotherapy (IC) for Acute Myeloid Leukemia (AML): Prospective geriatric assessment (GA) report from ECOG-ACRIN (EA) E2906 randomized study

Blood (2025) 146 (Supplement 1): 882.

https://doi.org/10.1182/blood-2025-882

Published: 2025

Journal Articles

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in acute myeloid leukemia (AML): An analysis of ECOG-ACRIN clinical trials

Douglas Tremblay, Li Chen, Zhuoxin Sun, Chezi Ganzel, Hugo Fernandez, James Foran, Daniel Arber, Hillard Lazarus, Yanming Zhang, Elisabeth Paietta, John Bennett, Jacob Rowe, Mark Litzow, Martin Tallman, Ehab Atallah, Selina Luger

Blood (2025) 146 (Supplement 1): 871.

https://doi.org/10.1182/blood-2025-871

Published: 2025

Journal Articles

Inferior survival in black AML patients treated with intensive chemotherapy in ECOG-ACRIN clinical trials is independent of cytogenetic profiles

Shella Saint Fleur-Lominy, Li Chen, Zhuoxin Sun, Francine Garrett-Bakelman, Mihir Shukla, Hugo Fernandez, James Foran, Larry Cripe, Hillard Lazarus, Peter Wiernik, Jacob Rowe, Martin Tallman, Mark Litzow, Yanming Zhang, Selina Luger, Irum Khan

Blood (2025) 146 (Supplement 1): 290.

https://doi.org/10.1182/blood-2025-290

Published: 2025

Journal Articles

Sparse whole genome sequencing and machine learning of AML genomes reveals novel, clinically relevant genetics.

Blood (2025) 146 (Supplement 1): 5263.

https://doi.org/10.1182/blood-2025-5263

Published: 2025

Journal Articles

Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries

Blood (2025) 146 (Supplement 1): 1739.

https://doi.org/10.1182/blood-2025-1739

Published: 2025

Journal Articles

Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 5120.

https://doi.org/10.1182/blood-2025-5120

Published: 2025

Journal Articles

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

Blood (2025) 146 (Supplement 1): 1549.

https://doi.org/10.1182/blood-2025-1549

Published: 2025

Journal Articles

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Blood (2025) 146 (Supplement 1): 992.

https://doi.org/10.1182/blood-2025-992

Published: 2025

Journal Articles

The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival

Kuo-Kai Chin, Brian Ball, Yasmin Abaza, Jessica Altman, Rahul Thakur, Moiez Ali, Andriy Derkach, Mark Geyer, Aaron Goldberg, Tamanna Haque, Meghan Thompson, Jae Park, Martin Tallman, Sheng Cai, Eunice Wang, Ibrahim Aldoss, Eytan Stein

Blood (2025) 146 (Supplement 1): 39.

https://doi.org/10.1182/blood-2025-39

Published: 2025

Journal Articles

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

Blood (2025) 146 (Supplement 1): 31.

https://doi.org/10.1182/blood-2025-31

Published: 2025

Journal Articles

Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia

Blood (2024) 144 (12): 1257–1270.

https://doi.org/10.1182/blood.2024023890

Published: 2024

Includes: Supplemental data

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood (2022) 140 (2): 112–120.

https://doi.org/10.1182/blood.2021014960

Published: 2022

Includes: Supplemental data

Journal Articles

Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center

Justin M Watts, MD, Ashwin Kishtagari, MBBS [Co-first author], Sean Devlin, PhD, Eytan M Stein, MD, Jae H Park, MD, Mario E Lacouture, MD, Martin Tallman, MD

Blood (2013) 122 (21): 5274.

https://doi.org/10.1182/blood.V122.21.5274.5274

Published: 2013

Journal Articles

Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL

Blood (2013) 121 (11): 1935–1943.

https://doi.org/10.1182/blood-2012-08-449918

Published: 2013

Includes: Supplemental data

Journal Articles

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

Jerald P. Radich, Kenneth J. Kopecky, Frederick R. Appelbaum, Suzanne Kamel-Reid, Wendy Stock, Greg Malnassy, Elisabeth Paietta, Martha Wadleigh, Richard A. Larson, Peter Emanuel, Martin Tallman, Jeff Lipton, A. Robert Turner, Michael Deininger, Brian J. Druker

Blood (2012) 120 (19): 3898–3905.

https://doi.org/10.1182/blood-2012-02-410688

Published: 2012

Journal Articles

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

Blood (2012) 119 (17): 4083–4090.

https://doi.org/10.1182/blood-2012-02-409763

Published: 2012

Journal Articles

BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 471.

https://doi.org/10.1182/blood.V116.21.471.471

Published: 2010

Journal Articles

Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60–75

Jeffrey E. Lancet, MD, Jorge E. Cortes, MD, Donna E. Hogge, MD, PhD, Martin Tallman, MD, Tibor Kovacsovics, MD, Lloyd E. Damon, MD, Ellen Ritchie, MD, Rami S. Komrokji, MD, Arthur C. Louie, MD, Eric J Feldman, MD

Blood (2010) 116 (21): 655.

https://doi.org/10.1182/blood.V116.21.655.655

Published: 2010

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Compared to Chemotherapy Only in Acute Myeloid Leukemia (AML) Patients 60 Years and Older: A Center for International Blood and Marrow Transplantation Research (CIBMTR)/ Cancer and Leukemia Group B (CALGB) Study.

Sherif Farag, MD, PhD, Kati Maharry, MAS, Waleska S. Perez, MPH, Mei-Jie Zhang, PhD, John F. DiPersio, MD, PhD, Donald Bunjes, MD, Guido Marcucci, M.D., Maria R. Baer, M.D., Richard A. Larson, MD, Martin Tallman, MD, Clara D. Bloomfield, M.D., Daniel J. Weisdorf, MD

Blood (2009) 114 (22): 657.

https://doi.org/10.1182/blood.V114.22.657.657

Published: 2009

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in acute myeloid leukemia (AML): An analysis of ECOG-ACRIN clinical trials

Inferior survival in black AML patients treated with intensive chemotherapy in ECOG-ACRIN clinical trials is independent of cytogenetic profiles

Sparse whole genome sequencing and machine learning of AML genomes reveals novel, clinically relevant genetics.

Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries

Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center

Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia

Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60–75

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Compared to Chemotherapy Only in Acute Myeloid Leukemia (AML) Patients 60 Years and Older: A Center for International Blood and Marrow Transplantation Research (CIBMTR)/ Cancer and Leukemia Group B (CALGB) Study.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only